MacroGenics, Inc.
$4.04
-$0.16 (-3.81%)
$3.99Day Range$4.19
Key Statistics
Market Cap
$257.35M
Shares Outstanding
63.7M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 10, 2013
Round Lot
100
Locale
US
Trading Data
Day Open
$4.19
Day High
$4.19
Day Low
$3.99
Volume
265.0K
VWAP
$4.05
Prev Close
$4.20
Transactions
--
Acc. Volume
--
About MacroGenics, Inc.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
PHARMACEUTICAL PREPARATIONSSIC 2834293 employees9704 MEDICAL CENTER DRIVE, Rockville, MD, 20850301-251-5172IPO Oct 10, 2013US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001125345
- Composite FIGI
- BBG000BM2SF8
- Share Class FIGI
- BBG001S9C8R7
- Ticker Root
- MGNX
- SIC Code
- 2834
About MacroGenics, Inc. (MGNX) Stock
MacroGenics, Inc. (MGNX) closed the 2026-09-15 session at $4.04, down 3.81% versus the previous close (-0.16). The stock opened at $4.19 and traded between $3.99 and $4.19 during that session. Session trading volume was 265K shares. The volume-weighted average price (VWAP) is $4.05.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
MacroGenics, Inc. has a market capitalization of $257.3 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. MGNX is listed on the XNAS exchange. The company employs approximately 293 people. MacroGenics, Inc. is headquartered in Rockville, MD. The recorded listing date is 2013-10-10.
On this page you can find market MGNX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.